论文部分内容阅读
目的探讨阿利吉仑联合依那普利治疗轻中度原发性高血压病的疗效及安全性。方法选取河北冶建医院2014—2015年收治的轻中度原发性高血压病患者164例,按照随机数字表法分为阿利吉仑组(口服阿利吉仑片)53例、依那普利组(口服马来酸依那普利片)54例和联合治疗组(口服阿利吉仑片和马来酸依那普利片)57例。比较3组患者治疗前后血压、肾素活性及血清血管紧张素Ⅱ(AngⅡ)水平和不良反应发生情况。结果治疗前,3组患者收缩压、舒张压、肾素活性及血清AngⅡ水平比较,差异无统计学意义(P>0.05)。治疗后,联合治疗组患者收缩压、舒张压、肾素活性、AngⅡ水平低于阿利吉仑组和依那普利组(P<0.05);依那普利组患者的肾素活性高于阿利吉仑组,AngⅡ水平低于阿利吉仑组(P<0.05)。3组患者均未出现低血压及心脑血管事件。结论阿利吉仑联合依那普利治疗轻中度原发性高血压病,可进一步降低血压水平,抑制肾素的释放,从而减少血清AngⅡ的生成。
Objective To investigate the efficacy and safety of aliskiren combined with enalapril in the treatment of mild to moderate essential hypertension. Methods 164 patients with mild-to-moderate essential hypertension admitted in Hebei Yayao Hospital from 2014 to 2015 were randomly divided into aliskiren group (oral aliskiren tablets) (53 cases), enalapril Group (oral enalapril maleate tablets) 54 cases and combined treatment group (oral aliskiren tablets and enalapril maleate tablets) in 57 cases. Blood pressure, renin activity, serum Angiotensin Ⅱ (AngⅡ) levels and adverse reactions were compared between the three groups before and after treatment. Results Before treatment, there was no significant difference in systolic blood pressure, diastolic blood pressure, renin activity and serum AngⅡ level between the three groups (P> 0.05). After treatment, the systolic blood pressure, diastolic blood pressure, renin activity and AngⅡ level were lower in the combined treatment group than those in the aliskiren and enalapril groups (P <0.05). The renin activity in the enalapril group was higher than that in the Alley Glutamine group, AngⅡ level was lower than the aliskiren group (P <0.05). No hypotension and cardiovascular events occurred in all three groups. Conclusion Aliskiren combined with enalapril treatment of mild to moderate essential hypertension can further reduce the level of blood pressure, inhibit the release of renin, thereby reducing the formation of serum Ang Ⅱ.